Single-Cell Regulatory Network Analysis Identifies Adjunctive Drug Candidates in Early Risankizumab-Treated Psoriasis.

INTRODUCTION: Risankizumab has demonstrated remarkable efficacy in the treatment of psoriasis; however, its long-term use faces multiple challenges, including high costs, reduced efficacy over time, and potential safety concerns, such as infections a…

Preview only. Read the full abstract at the source